Astrazeneca to Pay More Than $510 Million for Heptares Medicine

AstraZeneca Plc agreed to pay Heptares Therapeutics, a unit of Japan’s Sosei Group Corp., more than $510 million for the rights to develop and sell an experimental cancer medicine designed to harness the patient’s own immune system to help destroy tumors.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.